Health Canada has approved Zolgensma, a $2.8 million life-saving gene therapy for toddlers that replaces the dysfunctional gene which causes spinal muscular atrophy Type 1. As Morgan Black explains on the noon news, it’s exciting news for several Alberta families.
Global News at Noon Edmonton
$2.8M Zolgensma spinal muscular atrophy treatment approved by Health Canada
More Videos
-
Study finds brawn does not mean brains when it comes to the T.Rex
-
It’s opening day for the $34B Trans Mountain oil pipeline expansion
-
Alberta Municipalities ‘caught off guard’ by details of Bill 20
-
Mitigating fire risk in Edmonton
-
Edmonton special Olympic athlete chosen in local advertising campaign
-
Education minister highlights changes in new draft of social studies curriculum
You are viewing an Accelerated Mobile Webpage.
View Original Article